# US 2003/0077697 A1 · Novel serine/threonine protein-kinase like proteins and nucleic acids encoding the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077697 A1
- Document ID: US20030077697A1
- Status: Published application
- Kind: A1
- Application number: 09/898,837
- Filed: 2001-07-03
- Published: 2003-04-24
- Earliest claimed: 1999-11-17
- Inventors: Valerie L. Gerlach; John R. MacDougall; Kerry E. Quinn; Kumud Majumder; Kimberly A. Spytek; Corine Vernet; Catherine E. Burgess; Elma R. Fernandes; Luca Rastelli; John L. Herrmann; Steven K. Spaderna; Richard A. Shimkets; Raymond J. Taupier JR.
- Web page: https://patentgrep.com/patent/US20030077697A1

## CPC

- C12N 9/1205: {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a novel isolated SER5 polynucleotide and a polypeptide encoded by the SER5 polynucleotide. Also provided are the antibodies that immunospecifically bind to a SER5 polypeptide or any derivative, variant, mutant or fragment of the SER5 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the SER5 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states as well as other uses.

## Claims

### Claim 1

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
a) a mature form of the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15;
b) a variant of a mature form of the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
c) the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15;
d) a variant of the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and
e) a fragment of any of a) through d).

### Claim 2 (depends on 1)

The polypeptide of claim 1 that is a naturally occurring allelic variant of the sequence given by SEQ ID NO: 2, 6, 9, 11, or 15.

### Claim 3 (depends on 2)

The polypeptide of claim 2, wherein the variant is the translation of a single nucleotide polymorphism.

### Claim 4 (depends on 1)

The polypeptide of claim 1 that is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.

### Claim 5

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
a) a mature form of the amino acid sequence given SEQ ID NO: 2, 6, 9, 11, or 15;
b) a variant of a mature form of the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
c) the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15;
d) a variant of the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and
f) the complement of any of said nucleic acid molecules.

### Claim 6 (depends on 5)

The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant.

### Claim 7 (depends on 5)

The nucleic acid molecule of claim 5 that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant.

### Claim 8 (depends on 5)

The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a single nucleotide polymorphism encoding said variant polypeptide.

### Claim 9 (depends on 5)

The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of
a) the nucleotide sequence given by SEQ ID NO: 1, 5, 7, 8, 10, 14, 16, or 17;
b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence given by SEQ ID NO: 1, 5, 7, 8, 10, 14, 16, or 17 is changed from that given by the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed;
c) a nucleic acid fragment of the sequence given by SEQ ID NO: 1, 5, 7, 8, 10, 14, 16, or 17; and
d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence given by SEQ ID NO: 1, 5, 7, 8, 10, 14, 16, or 17 is changed from that given by the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

### Claim 10 (depends on 5)

The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence given by SEQ ID NO1, 5, 7, 8, 10, 14, 16, or 17, or a complement of said nucleotide sequence.

### Claim 11 (depends on 5)

The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence in which any nucleotide specified in the coding sequence of the chosen nucleotide sequence is changed from that given by the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides in the chosen coding sequence are so changed, an isolated second polynucleotide that is a complement of the first polynucleotide, or a fragment of any of them.

### Claim 12 (depends on 11)

A vector comprising the nucleic acid molecule of claim 11.

### Claim 13 (depends on 12)

The vector of claim 12, further comprising a promoter operably linked to said nucleic acid molecule.

### Claim 14 (depends on 12)

A cell comprising the vector of claim 12.

### Claim 15 (depends on 1)

An antibody that binds immunospecifically to the polypeptide of claim 1.

### Claim 16 (depends on 15)

The antibody of claim 15, wherein said antibody is a monoclonal antibody.

### Claim 17 (depends on 15)

The antibody of claim 15, wherein the antibody is a humanized antibody.

### Claim 18 (depends on 1)

A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
(a) providing said sample;
(b) introducing said sample to an antibody that binds immunospecifically to the polypeptide; and
(c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.

### Claim 19 (depends on 5)

A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
(a) providing said sample;
(b) introducing said sample to a probe that binds to said nucleic acid molecule; and
(c) determining the presence or amount of said probe bound to said nucleic acid molecule,
thereby determining the presence or amount of the nucleic acid molecule in said sample.

### Claim 20 (depends on 1)

A method of identifying an agent that binds to the polypeptide of claim 1, the method comprising:
(a) introducing said polypeptide to said agent; and
(b) determining whether said agent binds to said polypeptide.

### Claim 21 (depends on 1)

A method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of the polypeptide of claim 1, the method comprising:
(a) providing a cell expressing the polypeptide of claim 1 and having a property or function ascribable to the polypeptide;
(b) contacting the cell with a composition comprising a candidate substance; and
(c) determining whether the substance alters the property or function ascribable to the polypeptide;
whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent.

### Claim 22 (depends on 1)

A method for modulating the activity of the polypeptide of claim 1, the method comprising introducing a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.

### Claim 23 (depends on 1)

A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering the polypeptide of claim 1 to a subject in which such treatment or prevention is desired in an amount sufficient to treat or prevent said pathology in said subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein said subject is a human.

### Claim 25 (depends on 1)

A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a SERX nucleic acid in an amount sufficient to treat or prevent said pathology in said subject.

### Claim 26 (depends on 25)

The method of claim 25, wherein said subject is a human.

### Claim 27 (depends on 1)

A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a SERX antibody in an amount sufficient to treat or prevent said pathology in said subject.

### Claim 28 (depends on 15)

The method of claim 15, wherein the subject is a human.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 5)

A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 15)

A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically acceptable carrier.

### Claim 32 (depends on 29)

A kit comprising in one or more containers, the pharmaceutical composition of claim 29.

### Claim 33 (depends on 30)

A kit comprising in one or more containers, the pharmaceutical composition of claim 30.

### Claim 34 (depends on 31)

A kit comprising in one or more containers, the pharmaceutical composition of claim 31.

### Claim 35 (depends on 1)

A method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the polypeptide of claim 1, said method comprising:
a) administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of claim 1, wherein said test animal recombinantly expresses the polypeptide of claim 1;
b) measuring the activity of said polypeptide in said test animal after administering the compound of step (a); and
c) comparing the activity of said protein in said test animal with the activity of said polypeptide in a control animal not administered said polypeptide, wherein a change in the activity of said polypeptide in said test animal relative to said control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the polypeptide of claim 1.

### Claim 36 (depends on 38)

The method of claim 38, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.

### Claim 37 (depends on 1)

A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease,
wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.

### Claim 38 (depends on 5)

A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

### Claim 39

A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising the amino acid sequence given by SEQ ID NO: 2, 6, 9, 11, or 15 or a biologically active fragment thereof.

### Claim 40 (depends on 15)

A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.

### Claim 41

In isolated polypeptide according to claim I which is a) a mature form of the amino acid sequence given by SEQ ID NO: 1; b) a variant of a mature form of the amino acid sequence given by SEQ ID NO: 11, wherein any amino acid in the mature form is changed to a different amino acid provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; c) the amino acid sequence given by SEQ ID NO: 11; d) a variant of the amino acid sequence given by SEQ ID NO: 11, wherein any

### Claim 42 (depends on 41)

In isolated polypeptide according to claim 41 which is a) a mature form of the amino acid sequence given by SEQ ID NO: 11; b) a variant of a mature form of the amino acid sequence given by SEQ ID NO: 11, wherein any amino acid in the mature form is changed to a different amino acid provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; c) the amino acid sequence given by SEQ ID NO: 11; d) a variant of the amino acid sequence given by SEQ ID NO: 11, wherein any amino acid in the mature form is changed to a different amino acid provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; and e) a fragment of any of a) through d).

### Claim 43 (depends on 5)

An isolated nucleic acid molecule according to claim 5 which comprises a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: a) a mature form of the amino acid sequence given by SEQ ID NO: 11; b) a variant of a mature form of the amino acid sequence given by SEQ ID NO: 11, wherein any amino acid in the mature form is changed to a different amino acid provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; c) the amino acid sequence given by SEQ ID NO: 11; d) a variant of the amino acid sequence given by SEQ ID NO: 11, wherein any amino acid in the mature form is changed to a different amino acid provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence given by SEQ ID NO: 11 or any variant of said polypeptide wherein any amino acid sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and f) the complement of any of said nucleic acid molecules.

### Claim 44 (depends on 43)

The nucleic acid molecule of claim 43 wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of a) the nucleotide sequence given by SEQ ID NO: 10; b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence given by SEQ ID NO: 10 is changed from that given by the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; c) a nucleic acid fragment of the sequence given by SEQ ID NO: 10; and d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence given by SEQ ID NO: 10 is changed from that given by the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

### Claim 45 (depends on 44)

A vector comprising the nucleic acid molecule of claim 44.

### Claim 46 (depends on 45)

A cell comprising the vector of claim 45.

### Claim 47 (depends on 44)

A method for identifying a therapeutic agent for use in the treatment of a pathology wherein the pathology is related to aberrant expression or aberrant physiological interactions of the polypeptide of claim 44, the method comprising:
a) providing a cell expressing the polypeptide of claim 44 and having a property or function ascribable to the polypeptide;
b) contacting the cell with a composition comprising a candidate substance; and
c) determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance in step b) above is not observed when the cell is contacted with a composition devoid of that substance, then that substance is identified as a therapeutic agent.

### Claim 48 (depends on 44)

A pharmaceutical composition comprising the polypeptide of claim 44 and a pharmaceutically acceptable diluent or carrier.

### Claim 49 (depends on 44)

A method for determining the presence of or predisposition to a disease associated with altered levels of the the polypeptide of claim 44 in a first mammal, the method comprising: a) measuring the level of expression of the polypeptide in a sample from the first mammal; and b) comparing the amount of said polypeptide to an amount of the polypeptide present in a control sample from a second mammal in which the disease or predisposition to the disease is absent; wherein a difference in the expression level of the polypeptide of the first mammal as compared to that of the second mammal indicates the presence of or predisposition to the disease.
